These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10929034)

  • 1. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.
    Wada M; Mizoguchi H; Kuriya SI; Taguchi H; Kawamura T; Maekawa I; Shimazaki C; Sato Y; Niho Y; Miyazaki T; Shibata A; Kitani T; Hamajima N; Ohno R
    Br J Haematol; 2000 Jun; 109(4):805-14. PubMed ID: 10929034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New protocols for myeloma chemotherapy plus IFN alpha].
    Kitani T
    Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
    Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
    Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
    Salmon SE; Crowley JJ; Balcerzak SP; Roach RW; Taylor SA; Rivkin SE; Samlowski W
    J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
    Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
    Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
    Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
    Segeren CM; Sonneveld P; van der Holt B; Vellenga E; Croockewit AJ; Verhoef GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Fibbe WE; Wittebol S; Schouten HC; van Marwijk Kooy M; Biesma DH; Baars JW; Slater R; Steijaert MM; Buijt I; Lokhorst HM;
    Blood; 2003 Mar; 101(6):2144-51. PubMed ID: 12456509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)].
    Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A
    Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
    Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
    Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in the treatment of multiple myeloma].
    Wada M; Mizoguchi H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; Fett W; Fischer JT; Göbel B
    Eur J Cancer; 1995; 31A(2):146-51. PubMed ID: 7718318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
    Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
    Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
    Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
    Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
    Salmon SE; Beckord J; Pugh RP; Barlogie B; Crowley J
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):33-6. PubMed ID: 1948127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.